-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Estrella Immunopharma, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2021 to Q3 2024.
- Estrella Immunopharma, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$3.38M, a 80.5% decline year-over-year.
- Estrella Immunopharma, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$8.82M, a 18.5% decline year-over-year.
- Estrella Immunopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$7.31M, a 34.2% increase from 2023.
- Estrella Immunopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$11.1M, a 1016% decline from 2022.
- Estrella Immunopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$996K, a 302% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)